Thirty-seven patients with multiple myeloma (stage II and III, 65% increased ␤2-microglobulin level) were prospectively treated with a median of 3.7 VAD courses (range 2-8) followed by cyclophosphamide (6 g/m 
The treatment of multiple myeloma during the last three decades has consisted predominantly of alkylating agents. Long-term survivors are unusual with this treatment modality and the median survival duration is 24-36 months. 1, 2 Further increase in dose intensity can be obtained by performing autologous stem cell transplantation which can be facilitated by the use of peripheral blood stem cells isolated following cyclophosphamide treatment and granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage-CSF (GM-CSF). [3] [4] [5] Limited data are available regarding the optimal dose of hematopoietic growth factor (HGF) support. Demuynck et al 6 reported recently that G-CSF at a dose of 10 g/kg may be preferred because of its markedly lower toxicity and lower in-hospital costs in comparison to GM-CSF. However, it is not excluded that a lower dose of G-CSF might give similar results which can further reduce the costs related to the leukapheresis procedure. It was recently also suggested that oligoclonal serum Igs occurring post transplantation might be an independent prognostic factor for overall survival. 7 The oligoclonal serum Igs were shown in 10% of the patients following high-dose melphalan and/or total body irradiation. The present study was designed to define further the optimal dose of growth factor. In addition, the occurrence of oligoclonal serum Igs were evaluated in the total group of patients. Post transplantation, new oligoclonal serum Igs were demonstrated in 73% of the patients.
Patients, materials and methods

Patients and response criteria
Between August 1993 and April 1996 all patients at our department with high risk multiple myeloma were prospectively treated with autologous stem cell transplantation. Thirty-seven patients were included according to the following criteria: (1) age less than 65 years; (2) stage II or III according to the staging system of Durie and Salmon 8 and (3) serum creatinine Ͻ160 mol at the time of transplantation. Four patients were pretreated with two melphalan/prednisolone courses. Disease response was defined as follows: patients were regarded to have achieved complete remission (CR) when the original serum M-protein had disappeared, tested at least twice by immuno-electrophoresis according to Pascali et al; 9 no urine Mcomponent measurable (immuno-fixation in concentrated urine) and less than 5% plasma cells in the aspirate with a polyclonal immuno-staining defined with anti-kappa and anti-lambda. Patients were in partial remission (PR) if there was a 50% decrease in measurable M-protein or bone marrow infiltration (non-secretory or Bence-Jones myeloma) compared with pretreatment values. Patients with less than 50% reduction in serum M-protein were considered as non-responders.
Oligoclonal serum Igs different from the monoclonal serum protein at presentation were detected as described above. The oligoclonal Igs were determined every 3-4 months post transplantation and had to be present on different occasions.
All patients received as the induction regimen vincristine (0.4 mg/m ) followed by granulocyte colony-stimulating factor (G-CSF). Leukapheresis was performed with a COBE-Spectra machine (COBE, Dallas, TX, USA) and started at a leukocyte count Ͼ2.0 × 10 9 /l during the regeneration phase. The number of peripheral blood stem cells was identified by CD34-antigen expression measured by FACS analysis in combination with the number of colonyforming unit granulocyte-macrophage (CFU-GM) measured in an in vitro colony assay. 10 Two sources of G-CSF were used: lenograstim (Granocyte; Rhône Poulenc Rorer, Anthony, France) and filgrastim (Neupogen; Amgen, Thousand Oaks, CA, USA). Lenograstim is a human-identical glycosylated recombinant G-CSF whereas filgrastim is nonglycosylated recombinant-methionyl G-CSF. Lenograstim was given at a dose of 3.5 g/kg/day and filgrastim was given at a dose of 5.0 g/kg/day, both subcutaneously. Patients were prospectively randomized (lenograstim vs filgrastim). After normalization of peripheral blood counts patients were treated by etoposide 400 mg/m 2 i.v., cisplatinum 80 mg/m 2 i.v. on day 1, dexamethasone 40 mg orally for 4 days and ara-C 1000 mg/m 2 i.v. on day 5 (EDAP).
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Finally, the treatment was followed by high-dose melphalan (HDM, 200 mg/m 2 ) i.v. in combination with peripheral blood stem cell infusion. During the transplantation period patients were nursed in laminar air flow rooms according to the available facilities. Red blood cell transfusion was given at a hemoglobulin level of 8 g/dl or lower while a platelet transfusion was given at a platelet count of 10 × 10 9 /l or lower. No growth factor was applied after the infusion of peripheral blood stem cells.
Statistical analysis
The results of the study are based on an 'intention-to-treat' analysis. The Mann Whitney U test was used to define the difference between the growth factor combinations, the Kaplan-Meier product limit method for estimation of survival, and the log-rank test for comparison complete remission duration, event-free survival (EFS) and overall survival (OS).
Results
Patient characteristics
Thirty-seven patients were included in this study. The patients' characteristics are listed in Table 1 . Median age was 51 years (range 36-65) with 23 men and 14 women. According to the Durie-Salmon staging system 5% of the patients had stage II-A, 78% stage III-A and 16% stage III-B. Increased ␤2-microglobulin (␤2-M) levels were observed in 65% of the patients. The median ␤2-M level measured at presentation was 4.8 mg/l with a range of 1.0-17.6.
Treatment
The patients were treated with a median of 3.7 (range 2-8) VAD courses. After the VAD courses, the overall response was 81% and 16% of the patients had a CR. Peripheral stem cell (PSC) collection was performed in all patients following high-dose cyclophosphamide (6 g/m 2 ) and G-CSF. Fourteen patients received filgrastim at a dose of 5.0 g/kg whereas 22 patients received lenograstim at a dose of 3.5 g/kg. The total number of days of growth factor administration varied with both regimens between 8 and 12 days. Adequate stem cell mobilization was obtained in all patients. A median of 41 × 10 6 CD34 + cells/kg (range 4.5-161) was collected with the use of filgrastim in a median of 1.6 leukapheresis procedures (range 1-4). Comparable results were obtained with lenograstim. A median Table 1 Patients' characteristics at presentation Bone Marrow Transplantation sepsis. The other patients died during the transplantation period due to pneumonia and sepsis.
Long-term follow-up
Long-term follow-up could be evaluated in 33 patients. After transplantation 30% of the patients achieved a complete remission (CR) and 54% of the patients a PR. During a median follow-up of 33 months (range 3-51) 88.4% of the patients relapsed after a median of 28.6 months. A significant advantage in EFS was observed for patients with CR compared to PR (P = 0.004, Figure 1 ). The overall survival is 45% with a median survival time of 44.0 months (38.9-49.1, CI: 95%). Also a significant advantage in overall survival was observed for the CR patients compared to PR patients (P = 0.036, Figure 2) .
Oligoclonality
In 33 patients it was possible to study the development of oligoclonal serum Igs in the post-transplant period after PSCT (Table 2) . New oligoclonal Igs appeared in 24 (73%) patients after a median of 3 months (range 1-6 months). Sixteen patients showed multiple bands and a single serum band could be defined in eight patients. Predominantly IgGand IgG-gammopathies were noted each occurring in 38%. Nine cases showed IgM (18%), two cases IgA together with IgG and IgM. Lambda and kappa light chains appeared in 40% and 42% of the cases, respectively. Two patients with oligoclonal serum Igs in the post-transplant period died after 3 and 4 months, respectively, with the reappearance of the original malignant clone. In nine cases the oligoclonal serum Igs disappeared spontaneously after a median of 22 months (range 8-36) post transplantation.
Bone Marrow Transplantation In all these patients the immunofixation became negative. The additional 15 patients still had oligoclonal serum Igs with a median follow-up of 31 months (range 21-45). In the group of patients with oligoclonal serum Igs 10 patients (42%) died with a mean survival of 35 months (range 24-49). The mean survival of patients without oligoclonal serum Igs was not significantly different (P = 0.23) with this limited number of patients (Figures 3 and 4) .
Discussion
This study represents patients with high-risk multiple myeloma treated with high-dose melphalan supported by PBSC after induction therapy with VAD and EDAP courses. A total of 37 patients have been studied, most of them with advanced stage disease at presentation and three of them with plasma cell leukemia. A CR rate of 30% was obtained after the total treatment period. The decline in tumor activity was most pronounced after the VAD courses. The cyclophosphamide, EDAP and transplantation increased the CR rate from 16% to 30% which has clinical consequences since the EFS and overall survival are significantly better in the CR group compared to the non-CR group. The overall results are comparable with other studies with PSC transplantation.
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Peripheral blood stem cells could easily be collected after high-dose cyclophosphamide and G-CSF after one to two leukapheresis procedures. No advantage was observed for 5 g/kg filgrastrim over 3.5 g/kg lenograstim. With both forms of G-CSF high numbers of CD34 + cells were harvested in most cases, indicating that a much lower dose of G-CSF can be applied, as recently advised. 6 This will reduce further the costs related to the leukapheresis procedure. These data also reveal that the dose of growth factor used for stem cell mobilization seems to depend on the underlying disorder and chemotherapy. Recently, it was shown in acute myeloid leukemia that a dose of 400-600 g/m 2 lenograstim is required for collecting an adequate stem cell transplant after the combination chemotherapy of amsacrine and cytarabine. 15 A high incidence of oligoclonal serum Igs was observed post transplantation. In 73% of the patients oligoclonal serum Igs appeared after a median of 3 months post transplantation. In most cases IgG bands were observed. In the minority IgM or IgA bands were observed. The presence of an oligoclonal B cell proliferation is frequently noticed after allogeneic bone marrow transplantation. 16 In autologous bone marrow transplantation it has been noticed but the reported incidence is much lower as observed in the present study. [17] [18] [19] [20] The difference in frequency of oligoclonality between the various studies is unclear. The high incidence in the present study seems not to be related to a difference in the CR rate as was recently suggested by Zent et al. 7 The appearance of oligoclonal serum Igs might be 
